AddLife (LSE:0REZ) is one of Sweden's decentralised serial acquirers — a model Nordic investors have long revered, but one tested since interest rates rose and cheap Acquisition Debt disappeared. Spun out of Addtech and listed on Nasdaq Stockholm in 2016, AddLife grew rapidly by buying life-science and medical-technology distributors, only to run into Margin pressure and elevated Leverage as the cycle turned.
In its second-quarter 2026 report, published in July, the company struck a markedly more confident tone. Chief executive Fredrik Dalborg said AddLife's companies were performing well across the board, with stronger margins, good growth and increased cash flow. Investors agreed: the shares jumped roughly 41–42% after the report. The headline question is whether this marks a sustainable return to form for the MedTech roll-up, or a sharp relief rally in a heavily de-rated stock.
What the Company Does
AddLife describes itself as an independent partner in the life-science industry, operating across Europe through roughly 85 subsidiaries and around 2,300 employees, with annual net sales exceeding SEK 10 billion. It runs two divisions. Labtech supplies laboratory equipment, instruments, diagnostics and consumables to hospitals, research institutions and industrial customers. Medtech distributes medical devices across areas including surgery, homecare, ophthalmology and diagnostics.
The model is deliberately decentralised: dozens of entrepreneur-led subsidiaries operate with autonomy while the parent allocates Capital and pursues acquisitions. Growth comes from two engines — organic expansion and a steady stream of bolt-on deals funded largely by Cash Flow and debt. That delivered years of compounding returns, but left AddLife sensitive to the cost of debt, to end-market demand, and to acquisition prices. The recovery thesis hinges on proving both organic performance and disciplined dealmaking are back in balance.
Why the Stock Is in Focus
The catalyst is the Q2 2026 report and the unusually strong market reaction to it. After a prolonged period of underperforming shares and margin scrutiny, the quarter delivered the combination investors had waited for: growth, expanding margins and improving cash generation at once. A move of more than 40% shows how depressed sentiment had become.
Crucially, management framed the quarter as evidence its improvement initiatives are working, not as a one-off. Dalborg highlighted a shift towards more advanced products, which he argued create greater value for customers through improved clinical outcomes while supporting higher pricing and better margins, with recoveries in previously troubled areas such as homecare now contributing positively. For a serial acquirer whose case rests on compounding, that renewed confidence in the underlying trajectory was exactly what was needed.
Latest Financial Picture
The second-quarter numbers back the confident tone. Net sales rose 6% to SEK 2,721 million, from SEK 2,578 million, with organic growth of 4% (adjusted for the December 2025 divestment of a UK endoscopy business) and acquisitions adding three points. EBITA increased 11% to SEK 342 million, lifting the margin to 12.6% from 11.9%. Profit after tax jumped 30% to SEK 130 million, Earnings Per Share reached SEK 1.06 against SEK 0.83, and Operating Cash Flow improved to SEK 165 million from SEK 119 million.
The first-half picture is more measured but still positive. Net sales for January–June rose 2% to SEK 5,366 million, EBITA increased 4% to SEK 674 million at a 12.6% margin (from 12.3%), and profit after tax rose 17% to SEK 258 million, with EPS of SEK 2.11 versus SEK 1.81. The group reported net debt to EBITDA of 2.6x, below its 3.0x target, and net debt to Equity of 0.8x, within guideline. First-half operating cash flow of SEK 269 million was down from SEK 359 million, a reminder that cash conversion can be lumpy.
The Bull Case
The bull case is that AddLife's compounding machine is working again. Margins are expanding, organic growth has returned in both divisions — Labtech at 3% organic plus 4% from acquisitions, Medtech at 5% organically on an adjusted basis — and the Balance Sheet is back within target ranges, restoring firepower for deals. Management said recent acquisitions are already contributing clearly to earnings, with the pipeline active.
There is a structural argument too. AddLife operates in defensive healthcare end-markets underpinned by ageing populations and rising diagnostic demand, and the decentralised model offers a long runway of distributors to acquire across Europe. If leverage stays disciplined, the mix of organic growth, margin gains and accretive M&A is the recipe that made Nordic serial acquirers such powerful compounders.
The Bear Case
The bear case starts with valuation and expectations. A surge of more than 40% on a single report leaves little room for disappointment. Group organic growth of 4% is respectable but not spectacular, and first-half net sales growth of just 2% shows the recovery is still early and uneven.
Leverage, though improved, remains meaningful at 2.6x net debt to EBITDA, and the model's dependence on acquisitions means AddLife must keep finding sensibly-priced targets — harder in a competitive market. End-market softness is a live risk: management flagged headwinds in Spanish and UK capital-equipment markets, exposed to constrained hospital budgets. Currency, integration risk across dozens of subsidiaries, and renewed procurement pressure could all slow the recovery just as expectations have risen.
What Could Move the Stock Next?
The next scheduled catalyst is the third-quarter 2026 report, where investors will look for confirmation that margin expansion and organic growth are being sustained rather than flattering a single strong quarter. After the size of the post-results move, the market will be sensitive to any wobble.
Beyond earnings, acquisitions are the classic driver for a serial acquirer, and with leverage back within target the group can accelerate dealmaking; the price and quality of any bolt-ons will shape the narrative. Watch, too, the weaker end-markets management flagged — a stabilisation in Spanish and UK capital-equipment Demand would strengthen the story. Broader factors such as European interest rates and currency moves against the krona will also matter.
Outlook
Is the MedTech roll-up back on track for AddLife ? The Q2 2026 evidence is encouraging: growth, margins and profit all improved together, the balance sheet is back within target, and management sounded confident its self-help initiatives are delivering — exactly what a serial acquirer needs to rebuild trust. Yet the recovery is still young: first-half growth was modest, some end-markets remain soft, and a 40%-plus rally now bakes in higher expectations. On our reading, AddLife has done enough to show the model is functioning again, but proving this is a durable return to compounding, rather than a single strong quarter, will require the momentum to be repeated through the second half.






Please wait processing your request...